JNJ63576253 是具有口服活性的、有效的雄激素受体的完全拮抗剂，在 LNCaP 细胞中对 F877L 突变型 AR 和野生型 AR 的IC50值分别为 37 和 54 nM。它可用于研究去势抵抗性前列腺癌。

JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).

JNJ-63576253 inhibits the growth of VCaP cells,with an IC50 of 265nM[1].

2110428-64-1

C23H22ClF3N6O2S

538.97

DMSO:200mg/mL (371.08 mM)
H2O:insoluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years